September 29, 2026 Uncategorized BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting Read More
September 17, 2026 Uncategorized BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants Read More
September 14, 2026 Uncategorized BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants Read More
August 31, 2026 Uncategorized BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee Read More
August 28, 2026 Uncategorized BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants Read More
August 24, 2026 Uncategorized BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants Read More
August 19, 2026 Uncategorized BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer Read More
July 13, 2026 Uncategorized BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism Read More
July 9, 2026 Uncategorized BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee Read More
July 6, 2026 Uncategorized BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1 Read More
